PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME
Objective: To study the psychocognitive status of patients with arterial hypertension (AH) combined with post-COVID syndrome (PCS). Methods: A prospective cohort study involved 134 patients (84 men and 50 women), mean age 62.4±0.6 years, with AH (controlled arterial hypertension, Grade 1-3). The duration of AH was 5.6±0.2 years. Among them 73 patients and a history of COVID-19 infection (confirmed SARS-CoV-2 infection; duration more than 12 weeks) with subsequent development of PCS, while 61 patients did not have a history of COVID-19. Patients with PCS which were diagnosed with depressive syndrome, were further divided into two subgroups depending on agomelatine intake (those who received this medication and those who refused). A general clinical examination and psychodiagnostics were carried out using validated methods, such as HADS and SPMSQ. Statistical analysis was carried out in the RStudio program. Results: Based on the HADS questionnaire, patients with PCS demonstrated a higher rate of depressive syndrome compared to the patients without a history of COVID-19 (41% vs. 12%, p<0.001). Based on the severity of depressive syndrome, the following rates were found in the groups: subclinically expressed depression – in 26% of patients with PCS vs. 12% of patients without COVID-19 (p<0.001), clinically pronounced depression (only in the group of patients with PCS) – in 15% (p=0.007). Additionally, in patients with PCS psychocogniцtive function was assessed using SPMSQ questionnaire; among them those receiving agomelatine showed significantly less frequent and severe psychocognitive dysfunction compared to those who refuse the medication intake (32% vs. 94%, p=0.001). Conclusion: Patients with PCS are characterized by a more severe manifestation of anxiety-depressive syndrome, and the use of agomelatine shows statistically significant effectiveness in this category of patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Паёми Сино - 26(2024), 1, Seite 10-17 Zur Gesamtaufnahme - volume:26 |
|---|
| Sprache: |
Englisch ; Russisch |
|---|
| Beteiligte Personen: |
L.A. SHPAGINA [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Agomelatine |
|---|
| doi: |
10.25005/2074-0581-2024-26-1-10-17 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ097314455 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ097314455 | ||
| 003 | DE-627 | ||
| 005 | 20240413181408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.25005/2074-0581-2024-26-1-10-17 |2 doi | |
| 035 | |a (DE-627)DOAJ097314455 | ||
| 035 | |a (DE-599)DOAJcf05532dfe254cf4b647d64e08160df3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 050 | 0 | |a RA1-1270 | |
| 100 | 0 | |a L.A. SHPAGINA |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective: To study the psychocognitive status of patients with arterial hypertension (AH) combined with post-COVID syndrome (PCS). Methods: A prospective cohort study involved 134 patients (84 men and 50 women), mean age 62.4±0.6 years, with AH (controlled arterial hypertension, Grade 1-3). The duration of AH was 5.6±0.2 years. Among them 73 patients and a history of COVID-19 infection (confirmed SARS-CoV-2 infection; duration more than 12 weeks) with subsequent development of PCS, while 61 patients did not have a history of COVID-19. Patients with PCS which were diagnosed with depressive syndrome, were further divided into two subgroups depending on agomelatine intake (those who received this medication and those who refused). A general clinical examination and psychodiagnostics were carried out using validated methods, such as HADS and SPMSQ. Statistical analysis was carried out in the RStudio program. Results: Based on the HADS questionnaire, patients with PCS demonstrated a higher rate of depressive syndrome compared to the patients without a history of COVID-19 (41% vs. 12%, p<0.001). Based on the severity of depressive syndrome, the following rates were found in the groups: subclinically expressed depression – in 26% of patients with PCS vs. 12% of patients without COVID-19 (p<0.001), clinically pronounced depression (only in the group of patients with PCS) – in 15% (p=0.007). Additionally, in patients with PCS psychocogniцtive function was assessed using SPMSQ questionnaire; among them those receiving agomelatine showed significantly less frequent and severe psychocognitive dysfunction compared to those who refuse the medication intake (32% vs. 94%, p=0.001). Conclusion: Patients with PCS are characterized by a more severe manifestation of anxiety-depressive syndrome, and the use of agomelatine shows statistically significant effectiveness in this category of patients. | ||
| 650 | 4 | |a anxiety-depressive syndrome | |
| 650 | 4 | |a depression | |
| 650 | 4 | |a agomelatine | |
| 650 | 4 | |a valdoxan | |
| 650 | 4 | |a post-covid syndrome | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a arterial hypertension. | |
| 653 | 0 | |a Public aspects of medicine | |
| 700 | 0 | |a I.S. SHPAGIN |e verfasserin |4 aut | |
| 700 | 0 | |a L.D. KHIDIROVA |e verfasserin |4 aut | |
| 700 | 0 | |a A.A. VASILENKO |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Паёми Сино |g 26(2024), 1, Seite 10-17 |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:1 |g pages:10-17 |
| 856 | 4 | 0 | |u https://doi.org/10.25005/2074-0581-2024-26-1-10-17 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/cf05532dfe254cf4b647d64e08160df3 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.25005/2074-0581-2024-26-1-10-17 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2074-0581 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2959-6327 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 1 |h 10-17 | ||